Before revision:  The efficacy predictor is used to optimize the generated molecules through a reward determined by the predicted IC50 drug sensitivity for the generated molecule and the target profile .
After revision:  The generative process is optimized through PaccMann, a previously developed drug sensitivity prediction model to obtain effective anticancer compounds for the given context (i.e., transcriptomic profile) .